Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment

ATLANTA and MIAMI, March 19, 2020 /PRNewswire/ — Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced a collaboration to rapidly advance DRIVE’s EIDD-2801, a promising oral COVID-19 treatment, into human testing. This collaboration combines Ridgeback’s unique experience advancing drug development efforts in the midst of an on-going disease outbreak with the three decades of experience that the DRIVE executive team has in antiviral drug development and commercialization.

Source: Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment


The article was originally published here!

Comments

Popular posts from this blog

First migrant facility for children opens under Biden in Carrizo, Texas – The Washington Post

Pier 1 Closing All Stores For Good, Cites ‘New Reality, Uncertainty Of Post-COVID World’

Wave of evictions expected as moratoriums end in many states